<DOC>
	<DOCNO>NCT02899988</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy study drug LY3074828 participant moderate severe plaque psoriasis .</brief_summary>
	<brief_title>A Study LY3074828 Participants With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Present chronic plaque psoriasis base investigator confirm diagnosis chronic psoriasis vulgaris least 6 month prior baseline meet follow criterion : plaque psoriasis involve ≥10 % body surface area ( BSA ) absolute PASI score ≥12 affect skin screening baseline sPGA score ≥3 screen baseline Candidate biologic treatment psoriasis . Have history presence cardiovascular , respiratory , hepatic , gastrointestinal , endocrine , hematological , neurological , neuropsychiatric disorder serious and/or unstable illness , opinion investigator , could constitute risk take investigational product could interfere interpretation data . Breastfeeding nursing ( lactate ) woman . Have serious , opportunistic , chronic/recurring infection within 6 month prior screen . Have receive live vaccine ( ) ( include attenuate live vaccine ) within 1 month screen intend study . Have skin condition ( exclude psoriasis ) would affect interpretation result . Have receive systemic nonbiologic psoriasis therapy phototherapy within 28 day prior baseline . Have receive topical psoriasis treatment within 14 day prior baseline . Have receive antitumor necrosis factor ( TNF ) biologics , antiinterleukin ( IL ) 17 target biologics within 8 week prior baseline . Have previous exposure biologic therapy target IL23 ( include ustekinumab ) , either license investigational ( previous briakinumab use permit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>IL-23</keyword>
	<keyword>dermatology</keyword>
</DOC>